OasisLMS

Release Date: August 30, 2024

Expiration Date: August 29, 2027

This recorded webinar explores the rapidly evolving role of artificial intelligence (AI) in neuromodulation and its potential to transform patient care and treatment outcomes. Expert faculty provide an overview of current AI applications in neuromodulation, examine emerging clinical evidence, and discuss how advanced algorithms may enhance decision-making, therapy optimization, and personalized patient management.

The activity also addresses important challenges associated with integrating AI into clinical practice, including ethical considerations, implementation barriers, and responsible use of AI-driven technologies. Through faculty presentations and discussion, learners will gain a deeper understanding of the current landscape of AI in neuromodulation, evaluate its opportunities and limitations, and explore future directions for research and clinical innovation in this rapidly advancing field.

To access the NANS eLearning Center and register for this content, log in using your NANS account username and password.

• Have a NANS account? Click Login.
• Need an account? Click Create Account and complete the form.
• Questions about your NANS account? Email membership@nans.org or call (773) 648-7845 (Mon–Fri, 8:30 AM–5:00 PM CT).

Pain, neurosurgeons, neurology, pain, residents, fellows, APPs

Following participation in this activity, learners will be able to:

• Describe the current applications and benefits of AI in neuromodulation
• Identify the challenges and ethical considerations in integrating AI into neuromodulation therapies.
• Recognize future directions in AI-driven neuromodulation research and clinical practice.

Welcome
Yashar Eshraghi, MD   

Future Directions in AI Research and Applications
Christopher Robinson, MD, PhD

Introduction to AI and General Outlook
Alhed Altaha, MD

Navigating Challenges and Ethical Considerations in AI-Driven Neuromodulation
Ryan D'Souza, MD

The Role of AI in Neuromodulation and Emerging Clinical Evidence
Stephen Woloszynek, MD, PhD

Conclusion
Yashar Eshraghi, MD   

None of the planners, staff, reviewers or faculty have any relevant financial relationships to disclose with ACCME ineligible companies except those listed below. All relevant relationships have been mitigated. 

Disclosures